Cardiff Lexington Corporation · OTC:CDIX
Cardiff Lexington — Q3 2026 Earnings Presentation
10 slides from Cardiff Lexington's earnings presentation, Nov 16, 2026
Slide 1: Third Quarter 2026 Earnings Presentation
THIRD QUARTER 2026 EARNINGS PRESENTATION Monday, November 16, 2026 OTC: CDIX
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation does not constitute or form part of and should not be construed as, an offer to sell or issue or the solici tation of an offer to buy or subscribe for securities of Cardiff Lexington (the “Company”) in any jurisdiction or an inducement to enter into inves
Slide 3: Executive Summary: Cardiff Lexington by the Numbers
EXECUTIVE SUMMARY Cardiff Lexington by the Numbers YTD ended September 30, 2026 Operational & Strategic Updates 11 Nova Ortho and Spine locations • Continued strong demand for throughout Florida & Georgia healthcare services $6.3 M • Announced letter of intent for proposed acquisition of leading YTD
Slide 4: Letter of Intent for Proposed Acquisition of Leading Healthcare Platform
LETTER OF INTENT FOR PROPOSED ACQUISITION OF LEADING HEALTHCARE PLATFORM Transaction Overview Proposed Key Terms Target Established, multi-location musculoskeletal healthcare platform Up to $104M serving patients in multiple states Aggregate purchase price consideration Strategic Fit $30M $10M Compl
Slide 5: Third Quarter & YTD 2026 Financial Highlights
THIRD QUARTER & YTD 2026 FINANCIAL HIGHLIGHTS Three Months Ended Nine Months Ended 9/30/26 9/30/25 9/30/26 9/30/25 Revenue $1,912,179 $3,058,740 $6,294,016 $8,763,314 Cost of sales $875,420 $1,149,161 $2,756,887 $3,317,943 Gross profit $1,036,759 $1,909,579 $3,537,129 $5,445,371 Gross margin 54.2% 6
Slide 6: Balance Sheet Highlights
BALANCE SHEET HIGHLIGHTS Accounts Receivable Total Assets $23.4M $30.6M $22.1M $29.1M 12.31.25 9.30.26 12.31.25 9.30.26 5.9% Increase 5.2% Increase 6
Slide 7: Proven Business Model Supports Long-Term Strategy
PROVEN BUSINESS MODEL SUPPORTS LONG- TERM STRATEGY Proven Economic Model Demonstrated ability to drive growth and profitability in diverse economic markets and conditions Consistent Performance with Limited Working Capital Proven track record of driving return on invested capital Investing in Growth
Slide 8: Q&A
we 4 CARDIFF LEXINGTON CORPORATION Q&A
Slide 9: Appendix
we 4 CARDIFF LEXINGTON CORPORATION APPENDIX
Slide 10: Reconciliation of Non-GAAP Metrics
RECONCILIATION OF NON-GAAP METRICS Three months ended Nine months ended 9/30/26 9/30/25 9/30/26 9/30/25 Net Income (loss) before discontinued operations $(3,206,551) $(1,144,299) $(8,777,531) $(2,821,471) Adjustments to reconcile net income/(loss) to EBITDA Interest 2,468,536 1,765,528 6,516,692 4,5